Literature DB >> 15676133

[Primary prevention and treatment of latent tuberculosis infection with isoniazid: efficacy of a control program, 1997-2002].

A Martínez Sanchís1, J L Calpe Calpe, G Llavador Ros, J Ena Muñoz, A Calpe Armero.   

Abstract

OBJECTIVE: To analyze the efficacy of a specific program for the study and follow up of tuberculosis contacts. To study factors related to low adherence to treatment and to the development of liver toxicity caused by isoniazid. PATIENTS AND METHODS: Between December 1996 and December 2002, we found 458 contacts of 79 cases of pulmonary tuberculosis in patients uninfected by human immunodeficiency virus. The contacts were screened for tuberculosis infection and chemoprophylaxis was prescribed according to the recommendations of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR).
RESULTS: We identified 3 cases of tuberculosis among the contacts (prevalence 0.8%). Chemoprophylaxis with isoniazid was prescribed for 215 contacts. One hundred sixty-nine (79%) completed the prophylaxis protocol. The rate of adherence to treatment was lower in immigrants than in nonimmigrants (odds ratio, 3.42; 95% confidence interval, 1.03-11.04; P=.02). Forty-three patients (22%) developed liver toxicity during treatment, which had to be suspended in 3 cases. Duration of chemoprophylaxis was the only independent variable associated with liver toxicity (odds ratio, 3.80; 95% confidence interval, 1.10-13.13; P=.03).
CONCLUSIONS: Our study demonstrates the effectiveness of a specific program of study and follow up of tuberculosis contacts. Immigrants require tailored strategies to improve their adherence to the program. The duration of chemo-prophylaxis plays an important role in the development of liver toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15676133     DOI: 10.1016/s1579-2129(06)60391-1

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  4 in total

1.  Prophylactic effect of a therapeutic vaccine against TB based on fragments of Mycobacterium tuberculosis.

Authors:  Cristina Vilaplana; Olga Gil; Neus Cáceres; Sergio Pinto; Jorge Díaz; Pere-Joan Cardona
Journal:  PLoS One       Date:  2011-05-24       Impact factor: 3.240

Review 2.  Risk factors associated with adverse reactions to antituberculosis drugs.

Authors:  Laíse Soares Oliveira Resende; Edson Theodoro Dos Santos-Neto
Journal:  J Bras Pneumol       Date:  2015 Jan-Feb       Impact factor: 2.624

3.  Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to tuberculosis at home in Guinea-Bissau: a prospective cohort study.

Authors:  Victor Francisco Gomes; Andreas Andersen; Grethe Lemvik; Christian Wejse; Ines Oliveira; Fina J Vieira; Luis José Carlos; Cesaltina da Silva Vieira; Peter Aaby; Per Gustafson
Journal:  BMJ Open       Date:  2013-03-26       Impact factor: 2.692

4.  Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid.

Authors:  Eleane de Oyarzabal; Lourdes García-García; Claudia Rangel-Escareño; Leticia Ferreyra-Reyes; Lorena Orozco; María Teresa Herrera; Claudia Carranza; Eduardo Sada; Esmeralda Juárez; Alfredo Ponce-de-León; José Sifuentes-Osornio; Robert J Wilkinson; Martha Torres
Journal:  J Immunol Res       Date:  2019-12-06       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.